MiMedx Group Inc (MDXG) has been under a strong bear grip, hence the stock is down -9.29% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 1.97% in the past 1 week. The stock has risen by 2.4% in the past week indicating that the buyers are active at lower levels, but the stock is down -7.03% in the past 4 weeks.
MiMedx Group Inc (NASDAQ:MDXG): The stock opened at $7.71 on Friday but the bulls could not build on the opening and the stock topped out at $7.86 for the day. The stock traded down to $7.66 during the day, due to lack of any buying support eventually closed down at $7.67 with a loss of -0.13% for the day. The stock had closed at $7.68 on the previous day. The total traded volume was 901,566 shares.
The stock has recorded a 20-day Moving Average of 1.29% and the 50-Day Moving Average is 1.92%. MiMedx Group, Inc. is up 8.18% in the last 3-month period. Year-to-Date the stock performance stands at -18.14%.
MiMedx Group Inc (MDXG) : 6 Wall Street analysts covering MiMedx Group Inc (MDXG) believe that the average level the stock could reach for the short term is $11.5. The maximum price target given is $13 and the minimum target for short term is around $9, hence the standard deviation is calculated at $1.38.
MiMedx Group, Inc. (MiMedx) is an integrated developer, manufacturer and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane. The Companys biomaterial platform technologies include AmnioFix and EpiFix, its tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through its donor program, mothers delivering full-term Cesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. MiMedx processes the human amniotic membrane utilizing its Purion Process to produce an implant, which is referred as an allograft. MiMedx is the supplier of amniotic tissue, having supplied over 350,000 allografts for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare. Its CollaFix technology combines a means of creating fibers from soluble collagen and a cross-linking process.